Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema

Next Previous
X
Search
Trial Profile

A Multi-center, Randomized, Double-blind, Parallel, Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Fugan Ointment (ZL-3101) in Subjects With Subacute Eczema

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ZL 3101 (Primary)
  • Indications Eczema
  • Focus Therapeutic Use
  • Sponsors ZAI Lab

    • Most Recent Events

    • 22 Jan 2019 Status changed from recruiting to completed.
    • 24 Aug 2018 Primary endpoint has not been met. (Eczema Area and Severity Index (EASI) score changes from baseline to day 21), according to a ZAI Lab media release.
    • 24 Aug 2018 According to a ZAI Lab media release, based on the top-line results of this study, the company has decided to discontinue the development of ZL-3101 (Fugan) for the treatment of atopic dermatitis (AD). The study showed that drug was safe and well-tolerated, however, the treatment showed no efficacy differences between placebo and ZL-3101 .

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top